Author

Christian Berthou

EA2216, INSERM ERI29 - Cited by 14,630 - Immunologie - H

Biography

Dr. Christian Berthou from the Department of Haematology, University Hospital of Brest, France have research interest in Hematology, Lymphoma Clinical, Hematology,Chemotherapy,Flow Cytometry,Clinical Trials,Leukemia,Hematological Malignancies,Multiple Myeloma, Hematologic Diseases
Title
Cited by
Year
Multiple myeloma treatment in real-world clinical practice: results of a prospective, multinational, noninterventional study
M Mohty, E Terpos, MV Mateos, M Cavo, S Lejniece, M Beksac, ...Clinical Lymphoma Myeloma and Leukemia 18 (10), e401-e419, 2018201
72
2018
Early discontinuation of empirical antibacterial therapy in febrile neutropenia: the ANTIBIOSTOP study
L Le Clech, JP Talarmin, MA Couturier, JC Ianotto, C Nicol, R Le Calloch, ...Infectious Diseases 50 (7), 539-549, 2018201
70
2018
Administration of direct oral anticoagulants in patients with myeloproliferative neoplasms
JC Ianotto, MA Couturier, H Galinat, D Mottier, C Berthou, G Guillerm, ...International journal of hematology 106, 517-521, 2017201
54
2017
CD5 expression promotes IL-10 production through activation of the MAPK/Erk pathway and upregulation of TRPC1 channels in B lymphocytes
S Garaud, TE Taher, M Debant, M Burgos, S Melayah, C Berthou, ...Cellular & molecular immunology 15 (2), 158-170, 2018201
47
2018
Addition of androgens improves survival in elderly patients with acute myeloid leukemia: a GOELAMS study
A Pigneux, MC Béné, P Guardiola, C Recher, JF Hamel, M Sauvezie, ...J Clin Oncol 35 (4), 7-393, 2017201
38
2017
Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma
M Pertesi, M Vallée, X Wei, MV Revuelta, P Galia, D Demangel, J Oliver, ...Leukemia 33 (9), 2324-2330, 2019201
35
2019
Complement system: a neglected pathway in immunotherapy
A Bordron, C Bagacean, A Tempescul, C Berthou, E Bettacchioli, S Hillion, ...Clinical reviews in allergy & immunology 58, 155-171, 2020202
33
2020
Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia …
C Dartigeas, E Van Den Neste, J Léger, H Maisonneuve, C Berthou, ...The Lancet Haematology 5 (2), e82-e94, 2018201
31
2018
Consolidation anti-CD22 fractionated radioimmunotherapy with 90Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective …
F Kraeber-Bodere, A Pallardy, H Maisonneuve, L Campion, A Moreau, ...The Lancet Haematology 4 (1), e35-e45, 2017201
30
2017
Resistance to complement activation, cell membrane hypersialylation and relapses in chronic lymphocytic leukemia patients treated with rituximab and chemotherapy
A Bordron, C Bagacean, A Mohr, A Tempescul, B Bendaoud, S Deshayes, ...Oncotarget 9 (60), 31590, 2018201
29
2018
Autologous stem cell transplantation for primary mediastinal B-cell lymphoma: long-term outcome and role of post-transplant radiotherapy. A report of the European Society for …
I Avivi, A Boumendil, H Finel, A Nagler, AB de Sousa, JMR Santasusana, ...Bone marrow transplantation 53 (8), 1001-1009, 2018201
23
2018
Simulated patient and role play methodologies for communication skills and empathy training of undergraduate medical students
C Bagacean, I Cousin, AH Ubertini, M El Yacoubi El Idrissi, A Bordron, ...BMC medical education , 1-8,
20
2020
JAK2V617F and calreticulin mutations in recurrent venous thromboembolism: results from the EDITH prospective cohort
JC Ianotto, A Chauveau, D Mottier, V Ugo, C Berthou, E Lippert, A DellucAnnals of hematology 96, 383-386, 2017201
19
2017
Clinical characteristics of aquagenic pruritus in patients with myeloproliferative neoplasms
C Le Gall‐Ianotto, E Brenaut, M Gouillou, K Lacut, E Nowak, A Tempescul, ...British Journal of Dermatology 176 (1), 255-258, 2017201
18
2017
Combining cytogenetic and epigenetic approaches in chronic lymphocytic leukemia improves prognosis prediction for patients with isolated 13q deletion
C Bagacean, C Le Dantec, C Berthou, A Tempescul, H Saad, A Bordron, ...Clinical Epigenetics 9 (1), 1-11, 2017201
16
2017
Outcome of Ph negative myeloproliferative neoplasms transforming to accelerated or leukemic phase
LM Mollard, A Chauveau, F Boyer-Perrard, N Douet-Guilbert, R Houot, ...Leukemia & Lymphoma 59 (12), 2812-2820, 2018201
16
2018
High‐dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL‐GITMO
I Avivi, L Arcaini, VV Ferretti, A Boumendil, H Finel, G Milone, F Zaja, ...British journal of haematology 182 (6), 807-8, 2018201
15
2018
STIM1 at the plasma membrane as a new target in progressive chronic lymphocytic leukemia
M Debant, M Burgos, P Hemon, P Buscaglia, T Fali, S Melayah, ...Journal for immunotherapy of cancer 7, 1-13, 2019201
14
2019
17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia
C Bagacean, A Tempescul, D Ternant, A Banet, N Douet-Guilbert, ...Journal for ImmunoTherapy of Cancer 7, 1-5, 2019201
13
2019
Alterations in DNA methylation/demethylation intermediates predict clinical outcome in chronic lymphocytic leukemia
C Bagacean, A Tempescul, C Le Dantec, A Bordron, A Mohr, H Saad, ...Oncotarget 8 (39), 65699, 2017201
12
2017

Referred From: https://scholar.google.com/citations?user=jjikh7kAAAAJ&hl=fr

Cited by
Citations 14630
h-index 53
i10-index 195
Recommended Journals
Open Access Journals